Table 2.
Glycemic Outcomes in the Open-Loop Therapy Using Different Insulin Analogs for the Baseline and Adjusted In Silico Scenarios
| Baseline—Open-loop therapy |
Adjusted— Open-loop therapy |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Postprandial |
Overall |
Postprandial |
Overall |
|||||||||
| Aspart | Fiasp | AT247 | Aspart | Fiasp | AT-247 | Aspart | Fiasp | AT247 | Aspart | Fiasp | AT-247 | |
| Average of BG levels (mg/dL) | 173.3 (61.4) | 171.4 (60.9) | 168.5 (60.4) | 157.6 (59.5) | 157.2 (58.9) | 156.8 (58.1) | 175.4 (44.1) | 171.8 (42.5) | 166.2 (40.5) | 156.8 (44.5) | 155.1 (42.5) | 152.1 (40.2) |
| Time spent <54 mg/dL (%) | 0.7 (2.1) | 0.6 (1.8) | 0.6 (1.8) | 1.1 (2.3) | 1 (2.1)a | 0.9 (2)b | 0.2 (0.7) | 0.2 (0.8) | 0.2 (0.7) | 0.3 (0.9) | 0.2 (0.8)a | 0.3 (0.9)a |
| Time spent <70 mg/dL (%) | 3.2 (7.2) | 3.4 (7.6) | 3.9 (8.7) | 5 (9.5) | 4.8 (9.5)a | 4.7 (9.6)a | 0.9 (2.5) | 0.9 (2.5) | 1 (3) | 1.7 (4.1) | 1.6 (3.9)a | 1.7 (4.2)a |
| Time spent in 70–140 mg/dL (%) | 28.8 (31.4) | 29.7 (32.6) | 30.7 (33.8) | 37 (32.7) | 37.3 (33.8)a | 37.4 (35)a | 18.8 (20.8) | 20.7 (23) | 23.7 (26.2) | 35.4 (24.6) | 36.3 (25.9)b | 38.2 (27.8)b |
| Time spent in 70–180 mg/dL (%) | 53.5 (37.9) | 54.4 (38.3) | 55.1 (38.6) | 61.7 (33.1) | 62 (34)a | 62.2 (34.9)a | 55.5 (33.3) | 58.9 (33.8) | 64.4 (34) | 70.2 (25) | 72.2 (25.6)b | 75.3 (26.2)b |
| Time spent >180 mg/dL (%) | 43.3 (40.6) | 42.3 (41) | 41 (41.4) | 33.3 (36.4) | 33.1 (37)a | 33.1 (37.8)a | 43.6 (33.9) | 40.3 (34.4) | 34.5 (34.6) | 28.1 (25.8) | 26.2 (26.4)b | 23 (26.9)b |
| Time spent >250 mg/dL (%) | 11.5 (25.4) | 10.9 (25.1) | 10.1 (24.6) | 7.4 (17.9) | 7.2 (17.9)b | 6.9 (18.3)b | 5.2 (14.1) | 4 (12.6) | 2.6 (9.9) | 2.8 (8.1) | 2.2 (7.2)b | 1.4 (5.7)b |
| Coefficient of variation of BG levels (%) | 16.1 (7.1) | 15.4 (7.1) | 14.7 (7.8) | 19.5 (7.4) | 18.4 (7.3) | 17 (7.4) | 15.7 (6.1) | 15 (6) | 14 (6.6) | 20.5 (7.2) | 19.3 (7.1) | 17.6 (7.4) |
| Insulin delivered (U) | 38.7 (17.2) | 38.7 (17.3) | 38.9 (17.4) | 51.3 (22.9) | 51.4 (22.9) | 51.5 (23) | 38.5 (22.5) | 39.1 (22.8) | 40.4 (23.9) | 51.1 (27.2) | 51.7 (27.6) | 53 (28.5) |
Results presented as mean (standard deviation).
a
No statistically significant differences in glycemic metrics when switching from Aspart to Fiasp or AT247 for the overall period (P > 0.05).
b
Statistically significant differences in glycemic metrics when switching from Aspart to Fiasp or AT247 for the overall period (P < 0.05).
BG.